Moreover, low tumor mitotic activity was associated with better prognosis in LUAD subgroups with EGFR mutations or pan-negative (no oncogenic alteration in genes including KRAS, EGFR, BRAF, ERBB2, PIK3CA, ALK, and ROS1) but not in those with KRAS or BRAF mutations (Figure 3C–D, Figure 2—figure supplement 4H–I). The gene discussed is ROS1; the disease is neoplasm.